MKI67 and neoplasm: In our multidisciplinary tumor board, given the tumor’s T1 size, node negativity, and low Ki-67 (8%), we selected paclitaxel-carboplatin as adjuvant therapy to align with TNBC systemic coverage while avoiding anthracycline exposure.